Clinical Trials
75 trialsSAMETA
AstraZeneca
TroFuse-019
Merck Sharp & Dohme LLC
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
TROPION-Lung15
AstraZeneca
LITESPARK-033
Merck Sharp & Dohme LLC
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
Be6A Lung-02
Pfizer
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
AspiRe HCC
Curtin University
SAFFRON
AstraZeneca
AcceleRET-Lung
Hoffmann-La Roche
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
KEYLYNK-008
Merck Sharp & Dohme LLC
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
Mashhad University of Medical Sciences
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
COSMIC-312
Exelixis
ADRIATIC
AstraZeneca
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
FLAURA2
AstraZeneca
VITAL
Sanofi
COSMIC-313
Exelixis
PRIME-Lung
Trans Tasman Radiation Oncology Group
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
AEGEAN
AstraZeneca
NICAP
Eurofarma Laboratorios S.A.
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
LEO Pharma
PembroMetaRT
UNICANCER
OPTIMA
Imunon
GEOMETRY-E
Novartis
NEOPAN
UNICANCER
MRI
University of Chicago
CANOPY-2
Novartis
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
ATTAIN
Nektar Therapeutics
HPVOropharynx
Trans Tasman Radiation Oncology Group
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
INTEGRATEIIa
Australasian Gastro-Intestinal Trials Group
ALTA-1L
Takeda
IMpower130
Hoffmann-La Roche
METIV-HCC
Daiichi Sankyo
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
Blokhin's Russian Cancer Research Center
Olympus
UroGen Pharma Ltd.
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Steba Biotech S.A.
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Ipsen
Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer
ChineseAMS